Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 210

Sort by

Sort Order Select

Journal Articles

Frequent mutated B2M, EZH2 , IRF8 , and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Blood Adv (2021) 5 (19): 3760–3775.

https://doi.org/10.1182/bloodadvances.2021005215

Published: 2021

Includes: Supplemental data

Journal Articles

Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia

Carolina E. Morales, Elliot Stieglitz, Scott C. Kogan, Mignon L. Loh, Benjamin S. Braun

Blood Adv (2021) 5 (18): 3587–3591.

https://doi.org/10.1182/bloodadvances.2020003754

Published: 2021

Includes: Supplemental data

Journal Articles

A novel activating JAK1 mutation in chronic eosinophilic leukemia

William Shomali, Alisa Damnernsawad, Talent Theparee, David Sampson, Quinlan Morrow, Fei Yang, Sebastian Fernandez-Pol, Richard Press, James Zehnder, Jeffrey W. Tyner, Jason Gotlib

Blood Adv (2021) 5 (18): 3581–3586.

https://doi.org/10.1182/bloodadvances.2021004237

Published: 2021

Includes: Supplemental data

Journal Articles

Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events

Stefan Schmidt, Dimitri Daniliants, Elisabeth Hiller, Eberhard Gunsilius, Dominik Wolf, Clemens Feistritzer

Blood Adv (2021) 5 (18): 3515–3527.

https://doi.org/10.1182/bloodadvances.2020004061

Published: 2021

Includes: Supplemental data

Journal Articles

Germline variants in DNA repair genes, including BRCA1 / 2 , may cause familial myeloproliferative neoplasms

Miriam Elbracht, Robert Meyer, Kim Kricheldorf, Deniz Gezer, Eggermann Thomas, Beate Betz, Ingo Kurth, Lino L. Teichmann, Tim H. Brümmendorf, Ulrich Germing, Susanne Isfort, Steffen Koschmieder

Blood Adv (2021) 5 (17): 3373–3376.

https://doi.org/10.1182/bloodadvances.2021004811

Published: 2021

Journal Articles

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Blood Adv (2021) 5 (17): 3279–3289.

https://doi.org/10.1182/bloodadvances.2021004631

Published: 2021

Includes: Supplemental data

Journal Articles

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Inge van der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, Stephan Hutter, Constance Baer, Martijn Heymans, Peter J. M. Valk, Wolfgang Kern, Claudia Haferlach, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos, Torsten Haferlach

Blood Adv (2021) 5 (17): 3254–3265.

https://doi.org/10.1182/bloodadvances.2021004556

Published: 2021

Includes: Supplemental data

Journal Articles

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

Blood Adv (2021) 5 (16): 3203–3215.

https://doi.org/10.1182/bloodadvances.2021004976

Published: 2021

Includes: Supplemental data

Journal Articles

B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations

Kathryn A. Six, Ulrike Gerdemann, Anna L. Brown, Andrew E. Place, Alan B. Cantor, Matthew A. Kutny, Serine Avagyan

Blood Adv (2021) 5 (16): 3199–3202.

https://doi.org/10.1182/bloodadvances.2021004653

Published: 2021

Journal Articles

Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL

Burcu Aslan, Gorkem Kismali, Lisa S. Chen, LaKesla R. Iles, Mikhila Mahendra, Michael Peoples, Mihai Gagea, Natalie W. Fowlkes, Xiaofeng Zheng, Jing Wang, Christopher P. Vellano, Joseph R. Marszalek, Maria Teresa Sabrina Bertilaccio, Varsha Gandhi

Blood Adv (2021) 5 (16): 3134–3146.

https://doi.org/10.1182/bloodadvances.2020003821

Published: 2021

Includes: Supplemental data

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Peter G. Miller, Adam S. Sperling, Elliott J. Brea, Mark B. Leick, Geoffrey G. Fell, Max Jan, Satyen H. Gohil, Yu-Tzu Tai, Nikhil C. Munshi, Catherine J. Wu, Donna S. Neuberg, Marcela V. Maus, Caron Jacobson, Christopher J. Gibson, Benjamin L. Ebert

Blood Adv (2021) 5 (15): 2982–2986.

https://doi.org/10.1182/bloodadvances.2021004554

Published: 2021

Includes: Supplemental data

Journal Articles

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial

Blood Adv (2021) 5 (14): 2901–2908.

https://doi.org/10.1182/bloodadvances.2020004144

Published: 2021

Includes: Supplemental data

Journal Articles

RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia

Stavroula Ntoufa, Marina Gerousi, Stamatia Laidou, Fotis Psomopoulos, Georgios Tsiolas, Theodoros Moysiadis, Nikos Papakonstantinou, Larry Mansouri, Achilles Anagnostopoulos, Niki Stavrogianni, Sarka Pospisilova, Karla Plevova, Antonios M. Makris, Richard Rosenquist, Kostas Stamatopoulos

Blood Adv (2021) 5 (13): 2788–2792.

https://doi.org/10.1182/bloodadvances.2020001717

Published: 2021

Includes: Supplemental data

Journal Articles

Alimam S, Villiers W, Dillon R, et al. Patients with triple-negative, JAK2 V617F- and CALR -mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059-1068.

Blood Adv (2021) 5 (12): 2575.

https://doi.org/10.1182/bloodadvances.2021005271

Published: 2021

Journal Articles

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Damodaran Narayanan, Olga Pozdnyakova, Robert P. Hasserjian, Sanjay S. Patel, Olga K. Weinberg

Blood Adv (2021) 5 (11): 2539–2549.

https://doi.org/10.1182/bloodadvances.2021004250

Published: 2021

Includes: Supplemental data

Journal Articles

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Blood Adv (2021) 5 (10): 2481–2489.

https://doi.org/10.1182/bloodadvances.2020003605

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Cheng-Hong Tsai, Jih-Luh Tang, Feng-Ming Tien, Yuan-Yeh Kuo, Dung-Chi Wu, Chien-Chin Lin, Mei-Hsuan Tseng, Yen-Ling Peng, Mei-Fang Hou, Yi-Kuang Chuang, Ming-Chih Liu, Chia-Wen Liu, Ming Yao, Liang-In Lin, Wen-Chien Chou, Chien-Yu Chen, Hsin-An Hou, Hwei-Fang Tien

Blood Adv (2021) 5 (10): 2456–2466.

https://doi.org/10.1182/bloodadvances.2020003738

Published: 2021

Includes: Supplemental data

Journal Articles

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

Cécile Tomowiak, Stéphanie Poulain, Charles Herbaux, Aurore Perrot, Béatrice Mahé, Pierre Morel, Thérèse Aurran, Olivier Tournilhac, Stéphane Leprêtre, Souad Assaad, Bruno Villemagne, Olivier Casasnovas, Delphine Nollet, Damien Roos-Weil, Sylvie Chevret, Véronique Leblond

Blood Adv (2021) 5 (9): 2438–2446.

https://doi.org/10.1182/bloodadvances.2020003895

Published: 2021

Includes: Supplemental data

Journal Articles

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3 -ITD–mutant AML

Suruchi Pacharne, Oliver M. Dovey, Jonathan L. Cooper, Muxin Gu, Mathias J. Friedrich, Sandeep S. Rajan, Maxim Barenboim, Grace Collord, M. S. Vijayabaskar, Hannes Ponstingl, Etienne De Braekeleer, Ruben Bautista, Milena Mazan, Roland Rad, Konstantinos Tzelepis, Penny Wright, Malgorzata Gozdecka, George S. Vassiliou

Blood Adv (2021) 5 (9): 2412–2425.

https://doi.org/10.1182/bloodadvances.2020003443

Published: 2021

Includes: Supplemental data

NARROW

Frequent mutated B2M, EZH2 , IRF8 , and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia

A novel activating JAK1 mutation in chronic eosinophilic leukemia

Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events

Germline variants in DNA repair genes, including BRCA1 / 2 , may cause familial myeloproliferative neoplasms

Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1

B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations

Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial

RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia

Alimam S, Villiers W, Dillon R, et al. Patients with triple-negative, JAK2 V617F- and CALR -mutated essential thrombocythemia share a unique gene expression signature. Blood Adv. 2021;5(4):1059-1068.

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML

Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3 -ITD–mutant AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only